Who are metformin+sibutramine's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/metformin-sibutramine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

metformin+sibutramine — Competitive Intelligence Brief

metformin+sibutramine (metformin+sibutramine) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antidiabetic agent + appetite suppressant combination. Area: Endocrinology / Diabetes.

marketed Antidiabetic agent + appetite suppressant combination AMP-activated protein kinase (metformin); serotonin and norepinephrine transporters (sibutramine) Endocrinology / Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

metformin+sibutramine (metformin+sibutramine) — Promomed, LLC. Metformin reduces hepatic glucose production and improves insulin sensitivity, while sibutramine suppresses appetite by inhibiting reuptake of serotonin and norepinephrine, together addressing hyperglycemia and weight management in type 2 diabetes.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
metformin+sibutramine TARGET	metformin+sibutramine	Promomed, LLC	marketed	Antidiabetic agent + appetite suppressant combination	AMP-activated protein kinase (metformin); serotonin and norepinephrine transporters (sibutramine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antidiabetic agent + appetite suppressant combination class)

Promomed, LLC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). metformin+sibutramine — Competitive Intelligence Brief. https://druglandscape.com/ci/metformin-sibutramine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab